Monopar Therapeutics Inc.
Monopar Therapeutics Inc. (MNPR) Revenue
Annual & quarterly revenue history · segment & region breakdown
MNPR · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsMonopar Therapeutics Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2015 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | — |
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
Compare revenue vs peers
BiotechnologyCompare MNPR revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Monopar Therapeutics Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Monopar Therapeutics Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Monopar Therapeutics Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
MNPR revenue · 4 questionsMNPR's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Monopar Therapeutics Inc. SEC filings · GAAP · Monopar Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026